| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology (Dr. Murman and Q. Chen, M.C. Powell, and S.B. Kuo), Medicine (Dr. Bradley), and Psychiatry (Dr. Colenda), Michigan State University, East Lansing.
Address correspondence and reprint requests to Dr. Daniel L. Murman, Department of Neurology, Michigan State University, B445 Clinical Center, East Lansing, MI 48824; e-mail: murman{at}msu.edu
Objective: To determine the incremental costs associated with behavioral symptoms in patients with AD.
Methods: A total of 128 patients with probable AD were enrolled into this study. Cognitive function and extrapyramidal features were assessed in patients with AD. Caregivers were interviewed to determine use of health care services, receipt of unpaid care, severity of behavioral symptoms (Neuropsychiatric Inventory [NPI]), and comorbid medical conditions in patients with AD. Healthcare utilization data were multiplied by unit costs to estimate direct formal costs. Unpaid caregiving hours were multiplied by an hourly wage to estimate direct informal costs. The annual incremental direct costs of additional behavioral symptoms were estimated with multiple regression equations.
Results: Annual, direct costs were significantly higher in patients with AD at or above the median score on the NPI (high NPI group), after adjusting for group differences in severity of cognitive impairment and comorbid conditions. Patients in the high NPI group had formal costs between $3,162 and $5,919 higher than the low NPI group and total direct costs between $10,670 and $16,141 higher, depending on the severity of cognitive impairments. Models for the entire sample estimated that a one-point increase in the NPI score would result in an annual increase of between $247 and $409 in total direct costs, depending on the value of unpaid caregiving.
Conclusions: Behavioral symptoms in patients with AD significantly increase direct costs of care.
This article has been cited by other articles:
|
|
 |
|
  S.-M. Tun, D. L. Murman, and C. C. Colenda Concurrent Validity of Neuropsychiatric Subgroups on Caregiver Burden in Alzheimer Disease Patients Am J Geriatr Psychiatry, July 1, 2008; 16(7): 594 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Sultzer, S. M. Davis, P. N. Tariot, K. S. Dagerman, B. D. Lebowitz, C. G. Lyketsos, R. A. Rosenheck, J. K. Hsiao, J. A. Lieberman, L. S. Schneider, et al. Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer's Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness Trial Am J Psychiatry, July 1, 2008; 165(7): 844 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-M. Tun, D. L. Murman, H. L. Long, C. C. Colenda, and A. von Eye Predictive Validity of Neuropsychiatric Subgroups on Nursing Home Placement and Survival in Patients With Alzheimer Disease Am J Geriatr Psychiatry, April 1, 2007; 15(4): 314 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Zhu, N. Scarmeas, R. Torgan, M. Albert, J. Brandt, D. Blacker, M. Sano, and Y. Stern Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease Neurology, September 26, 2006; 67(6): 998 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Cummings, E. Schneider, P. N. Tariot, S. M. Graham, and for the Memantine MEM-MD-02 Study Group Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology, July 11, 2006; 67(1): 57 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Zhu, N. Scarmeas, R. Torgan, M. Albert, J. Brandt, D. Blacker, M. Sano, and Y. Stern Clinical features associated with costs in early AD: Baseline data from the Predictors Study Neurology, April 11, 2006; 66(7): 1021 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kolanowski and M. L. Piven Geropsychiatric Nursing: The State of the Science Journal of the American Psychiatric Nurses Association, April 1, 2006; 12(2): 75 - 99. [Abstract] [PDF]
|
|
|
|
|
|
S.-H. Ryu, C. Katona, B. Rive, and G. Livingston Persistence of and Changes in Neuropsychiatric Symptoms in Alzheimer Disease Over 6 Months: The LASER-AD Study Am J Geriatr Psychiatry, November 1, 2005; 13(11): 976 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Lilly and M. R. Farlow Rivastigmine: An Open-Label Observational Study of Behavioral Symptoms Identified as Most Troubling by Caregivers of Patients With Alzheimer's Disease Journal of the American Psychiatric Nurses Association, October 1, 2005; 11(5): 293 - 297. [Abstract] [PDF]
|
|
|
|
|
|
D. Craig, A. Mirakhur, D. J. Hart, S. P. McIlroy, and A. P. Passmore A Cross-Sectional Study of Neuropsychiatric Symptoms in 435 Patients With Alzheimer's Disease Am J Geriatr Psychiatry, June 1, 2005; 13(6): 460 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Craig, D J Hart, K McCool, S P McIlroy, and A P Passmore Apolipoprotein E e4 allele influences aggressive behaviour in Alzheimer's disease J. Neurol. Neurosurg. Psychiatry, September 1, 2004; 75(9): 1327 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Murman, S. B. Kuo, M. C. Powell, and C. C. Colenda The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodies Neurology, October 14, 2003; 61(7): 944 - 949. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
